Skip to main content
. 2021 Apr 26;12:2442. doi: 10.1038/s41467-021-22708-w

Fig. 4. PAX8 and MECOM sustain ovarian cancer growth.

Fig. 4

A Barplot showing sensitivity to PAX8 or MECOM KO as per CRISPR screens reported in DepMap portal. Bars are color coded by MECOM expression. B, C Tumor volume measurements of NIH:OVCAR3 cells bearing shRNAs against PAX8 (B) or MECOM (C). Trt start = day of starting daily doxycycline treatment. *P < 0.01 and ***P < 0.0001 signify significantly and highly significant differences to the respective vehicle (two-sided t test post hoc) on the last treatment day. Data are presented as mean ± SEM from n > 5 mice cohorts. D Western blot analysis of tumors from (B) 1 week after treatment start. E Boxplot of z-score expression of PAX8–MECOM Signature (Sig. Score) in TCGA ovarian cases (n = 608) binned according to MECOM (left) or PAX8 (right) expression quartiles. Boxplots represent median and first and third quartiles, and whiskers extend to 95th percentile. P values are based on two-sided Wilcoxon’s rank-sum test. F Kaplan–Meier curve of survival from TCGA ovarian and endometrial patients bearing high or low levels of Signature Score (top and bottom quartile, n = 746). P P value from log-rank test. Source data for Western blots and qPCRs are provided as a Source Data file.